@article{2af13c966e7046c78361039ac24d886d,
title = "GDF15 Induces Anorexia through Nausea and Emesis",
abstract = "This work assesses whether or not GDF15 produces emesis and/or emetic-like behaviors in the vomiting shrew (Suncus murinus) and non-vomiting rat. The results suggest that exogenous delivery of GDF15 produces either emesis or emetic-like behavior (i.e., pica) prior to the induction of anorexia in shrews and rats, respectively.",
keywords = "GDF15, GFRAL, MIC-1, Suncus murinus, anorexia, chemotherapy, emesis, malaise, nausea, obesity",
author = "Tito Borner and Shaulson, {Evan D.} and Ghidewon, {Misgana Y.} and Barnett, {Amanda B.} and Horn, {Charles C.} and Doyle, {Robert P.} and Grill, {Harvey J.} and Hayes, {Matthew R.} and {De Jonghe}, {Bart C.}",
note = "Funding Information: The authors would like to thank Lauren Stein, Samantha Fortin, Rinzin Lhamo, and Rosa Leon for technical assistance. We also thank Bernard B. Allan for sharing his immunofluorescence protocol for GFRAL. This work was supported by NIH DK-112812 (B.C.D.), NIH DK-115762 (M.R.H.), NIH DK-021397 (H.J.G. and M.R.H.), NIH CA-201962 (C.C.H.), SNF P2ZHP3_178114 , and SNF P400PB_186728 (T.B.). Funding Information: The authors would like to thank Lauren Stein, Samantha Fortin, Rinzin Lhamo, and Rosa Leon for technical assistance. We also thank Bernard B. Allan for sharing his immunofluorescence protocol for GFRAL. This work was supported by NIH DK-112812 (B.C.D.), NIH DK-115762 (M.R.H.), NIH DK-021397 (H.J.G. and M.R.H.), NIH CA-201962 (C.C.H.), SNF P2ZHP3_178114, and SNF P400PB_186728 (T.B.). T.B. H.J.G. M.R.H. and B.C.D. developed the study rationale. T.B. designed, performed, and analyzed all the in vivo and molecular experiments, with E.D.S. M.Y.G. and A.B.B. performing technical assistance for in vivo experiments. C.C.H. provided technical assistance for the shrew experiments. T.B. and B.C.D. drafted the manuscript, which was commented on, edited, and approved by all authors. B.C.D. receives research funding from Eli Lilly & Co. and Pfizer, Inc. and provided remunerated consultancy services for cachexia-related projects for Pfizer, Inc. not supporting these studies. R.P.D. is a scientific advisory board member and received funds from Xeragenx LLC (St. Louis, NY) and Balchem, New Hampton, New York that were not used in support of these studies. M.R.H. receives research funding from Zealand Pharma, Novo Nordisk, Eli Lilly & Co. and Boehringer Ingelheim that was not used in support of these studies. H.J.G. is a consultant and advisory board member for Novo Nordisk and receives research support from Pfizer, Inc. that was not used to support these studies. T.B. M.R.H. B.C.D. and R.P.D. are co-inventors and owners of a patent for a proprietary compound related to the GDF15-GFRAL system (serial #: 62/801,391). No other competing interests are declared. Funding Information: B.C.D. receives research funding from Eli Lilly & Co. and Pfizer, Inc. and provided remunerated consultancy services for cachexia-related projects for Pfizer, Inc., not supporting these studies. R.P.D. is a scientific advisory board member and received funds from Xeragenx LLC (St. Louis, NY) and Balchem, New Hampton, New York that were not used in support of these studies. M.R.H. receives research funding from Zealand Pharma, Novo Nordisk, Eli Lilly & Co., and Boehringer Ingelheim that was not used in support of these studies. H.J.G. is a consultant and advisory board member for Novo Nordisk and receives research support from Pfizer, Inc. that was not used to support these studies. T.B., M.R.H., B.C.D., and R.P.D. are co-inventors and owners of a patent for a proprietary compound related to the GDF15-GFRAL system (serial #: 62/801,391). No other competing interests are declared. Publisher Copyright: {\textcopyright} 2019",
year = "2020",
month = feb,
day = "4",
doi = "10.1016/j.cmet.2019.12.004",
language = "English (US)",
volume = "31",
pages = "351--362.e5",
journal = "Cell Metabolism",
issn = "1550-4131",
publisher = "Cell Press",
number = "2",
}